XM levert geen diensten aan inwoners van de Verenigde Staten.

XM levert geen diensten aan inwoners van de Verenigde Staten.
B
B

BectonDickinson

Nieuws

Reuters - 3 weken geleden

BD Names Michael Feld As President Of Life Sciences Segment

BRIEF-BD Names Michael Feld As President Of Life Sciences Segment Aug 12 (Reuters) - Becton Dickinson and Co BDX.N : BD NAMES MICHAEL FELD AS PRESIDENT OF LIFE SCIENCES SEGMENT Source text for Eikon: ID:nPn6CCzVCa Further company coverage: BDX.N ( Reuters.Briefs@thomsonreuters.com )
B
Reuters - 4 weken geleden

U.S. Apple, Centerpoint Energy, Cummins

U.S. RESEARCH ROUNDUP-Apple, Centerpoint Energy, Cummins Aug 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Apple, Centerpoint Energy and Cummins, on Friday. HIGHLIGHTS * Apple Inc AAPL.O : Wedbush raises target price to $285 from $275 * Centerpoint Energy CNP.N : JP Morgan cuts to neutral from overweight * Cummins CMI.N : Jefferies raises target price to $365 from $345 * Motorola MSI.N : JP Morgan raises target pr
A
A
B
B
I
K
M
A
B
C
A
A
A
A
C
C
L
M
Reuters - 4 weken geleden

U.S. STOCKS Spirit Airlines, Labcorp, Air Products and Chemicals

BUZZ-U.S. STOCKS ON THE MOVE-Spirit Airlines, Labcorp, Air Products and Chemicals Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes fell over 1% on Thursday, bogged down by megacap tech and chip stocks, while small-caps bore the brunt of selling pressure as weak manufacturing data renewed concerns around a slowdown in the U.S.
B
I
J
Q
W
C
U
U
A
B
F
L
T
Reuters - 4 weken geleden

Becton falls on Q3 revenue miss

BUZZ-Becton falls on Q3 revenue miss ** Shares of medical device maker Becton Dickinson BDX.N fall 5.2% to $228.61 premarket ** Co reports Q3 revenue of $4.99 bln, missing analysts' average expectation of $5.08 bln ** Posts adj. profit of $3.50/shr vs analysts' average estimate of $3.31/shr - LSEG data ** Co raises the lower end of its full-year adj.
B
Reuters - 4 weken geleden

Becton Dickinson tops profit estimates on demand for drug-delivery devices

Becton Dickinson tops profit estimates on demand for drug-delivery devices Aug 1 (Reuters) - Becton Dickinson BDX.N reported a better-than-expected third -quarter profit on Thursday , helped by strong demand for its drug-delivery devices. Medical technology firms such as Becton, Boston Scientific BSX.N and Abbott Laboratories ABT.N are benefiting from a boost in demand as more people, especially older patients, catch up on surgeries that were put on hold during the pandemic.
A
B
Reuters - 4 weken geleden

Becton Dickinson Q3 Adjusted EPS USD 3.5 Vs. IBES Estimate USD 3.31

BRIEF-Becton Dickinson Q3 Adjusted EPS USD 3.5 Vs. IBES Estimate USD 3.31 Aug 01 (Reuters) - Becton Dickinson Q3 revenue USD 4,990 million vs. IBES estimate USD 5,076 million. Q3 EPS USD 1.68 outlook FY adjusted EPS USD 13.05-13.15
B
Reuters - 4 weken geleden

What to Watch in the Day Ahead - Thursday, August 1

What to Watch in the Day Ahead - Thursday, August 1 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Apple is expected to report a rise in third-quarter revenue, helped by higher iPad sales from new launches and strength in its services business.
A
A
B
C
I
K
V
M
B
Reuters - 1 maand geleden

Becton Dickinson and Co <BDX.N> expected to post earnings of $3.31 a share - Earnings Preview

Becton Dickinson and Co expected to post earnings of $3.31 a share - Earnings Preview Becton Dickinson and Co BDX.N , BDX is expected to show a rise in quarterly revenue when it reports results on August 1 for the period ending June 30 2024 The Franklin Lakes New Jersey-based company is expected to report a 4.1% increase in revenue to $5.076 billion from $4.88 billion a year ago, according to the mean estimate from 13 analysts, based on LSEG data.
B
Reuters - 1 maand geleden

BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases

BRIEF-BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases July 25 (Reuters) - Becton Dickinson and Co BDX.N : BD: CO, QUEST DIAGNOSTICS TO DEVELOP, MANUFACTURE AND COMMERCIALIZE FLOW CYTOMETRY-BASED COMPANION DIAGNOSTICS BD: OFFERINGS WILL INCLUDE EXPLORATORY PANEL DEVELOPMENT, MANUFACTURING & DISTRIBUTION
B
Reuters - 1 maand geleden

Edwards Lifesciences falls after missing Q2 revenue estimates

BUZZ-Edwards Lifesciences falls after missing Q2 revenue estimates ** Shares of medical device maker Edwards Lifesciences EW.N fall more than 16% to $72.7 in after-hours trading ** Co misses Q2 revenue estimates, hurt by lower-than-expected demand for its artificial heart valves ** Posts revenue of $1.39 bln, missing analysts' estimates of $1.65 bl
B
Reuters - 1 maand geleden

Edwards Lifesciences misses Q2 revenue estimates on weak demand for heart devices

REFILE-Edwards Lifesciences misses Q2 revenue estimates on weak demand for heart devices Corrects day in first paragraph July 24 (Reuters) - Edwards Lifesciences EW.N missed second-quarter revenue estimates on W ednesday , hurt by lower-than-expected demand for its artificial heart valves. Shares of the California-based company were down 14.3% at $74.50 after the bell.
A
B
Reuters - 1 maand geleden

BD Board Declares Dividend

BRIEF-BD Board Declares Dividend July 23 (Reuters) - Becton Dickinson and Co BDX.N : BD - DECLARED A QUARTERLY DIVIDEND OF $0.95 PER COMMON SHARE Source text for Eikon: ID:nPn2W8Q9Ca Further company coverage: BDX.N
B
Reuters - 2 maanden geleden

US FDA flags shortage of Becton Dickinson's blood test tubes

US FDA flags shortage of Becton Dickinson's blood test tubes July 10 (Reuters) - The U.S. Food and Drug Administration issued an alert on Wednesday to laboratories and healthcare providers of a shortage of Becton Dickinson' BDX.N blood test tubes used in diagnosing bacterial and fungal infections. The regulator urged providers to prioritize patients at the highest risk such as those displaying signs of bloodstream infections, which can often be deadly.
B
Reuters - 2 maanden geleden

BD Says Supplier Issue With Bactec Blood Culture Vials Not Expected To Have Material Financial Impact

BRIEF-BD Says Supplier Issue With Bactec Blood Culture Vials Not Expected To Have Material Financial Impact July 10 (Reuters) - Becton Dickinson and Co BDX.N : BD STATEMENT ON SUPPLIER ISSUE IMPACTING BD BACTEC™ BLOOD CULTURE VIALS BD: EXPERIENCING REDUCED AVAILABILITY OF BLOOD CULTURE VIALS FROM OUR SUPPLIER BD - SUPPLIER ISSUE IS NOT EXPECTED T
B
Reuters - 2 maanden geleden

FDA Says Aware That U.S. Is Experiencing Interruptions In The Supply Of Bd Bactec Blood Culture Media Bottles Because Of Recent Supplier Issues

BRIEF-FDA Says Aware That U.S. Is Experiencing Interruptions In The Supply Of Bd Bactec Blood Culture Media Bottles Because Of Recent Supplier Issues July 10 (Reuters) - FDA: AWARE THAT U.S. IS EXPERIENCING INTERRUPTIONS IN THE SUPPLY OF BD BACTEC BLOOD CULTURE MEDIA BOTTLES BECAUSE OF RECENT SUPPLIER ISSUES FDA: DISRUPTION IN SUPPLY OF BD BACTEC BLOOD CULTURE MEDIA BOTTLES IN U.S.
B
Reuters - 2 maanden geleden

U.S. Nvidia, Qualcomm, Tesla

U.S. RESEARCH ROUNDUP-Nvidia, Qualcomm, Tesla July 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Nvidia, Qualcomm and Tesla, on Wednesday. HIGHLIGHTS * Brighthouse Financial Inc BHF.O : Jefferies raises to buy from hold * Legalzoom.Com Inc LZ.O : JP Morgan cuts to neutral from overweight * Nvidia Corp NVDA.O : KeyBanc raises target price to $180 * Qualcomm Inc QCOM.O : KeyBanc raises target price to $225 * Tesla
A
A
A
A
A
C
G
M
M
N
P
Q
S
T
A
A
A
C
O
B
T
A
A
A
A
C
G
L
U
Reuters - 3 maanden geleden

U.S. Adobe, Oracle, Zscaler

U.S. RESEARCH ROUNDUP-Adobe, Oracle, Zscaler June 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Oracle Corp and Zscaler, on Friday. HIGHLIGHTS * Adobe Inc ADBE.O : Baird raises target price to $545 from $525 * Bandwidth Inc BAND.O : Morgan Stanley cuts to underweight from equal-weight * Corpay Inc CPAY.N : Jefferies cuts target price to $295 from $330 * Oracle Corp ORCL.N : Berenberg raises target price t
A
A
A
B
H
H
M
B
C
D
Reuters - 3 maanden geleden

Becton, Dickinson And Co Files For Offering Of $600 Million 5.081% Notes Due 2029 - SEC Filing

BRIEF-Becton, Dickinson And Co Files For Offering Of $600 Million 5.081% Notes Due 2029 - SEC Filing June 4 (Reuters) - Becton Dickinson and Co BDX.N : BECTON, DICKINSON AND CO FILES FOR OFFERING OF $600 MILLION 5.081% NOTES DUE 2029 - SEC FILING Source text for Eikon: [ID:n0001140361-24-028860] Further company coverage: BDX.N
B
Reuters - 3 maanden geleden

Becton Dickinson Euro Finance S.À R.L Files For Offering Of €800 Million 4.029% Notes Due 2036 - SEC Filing

BRIEF-Becton Dickinson Euro Finance S.À R.L Files For Offering Of €800 Million 4.029% Notes Due 2036 - SEC Filing June 4 (Reuters) - Becton Dickinson and Co BDX.N : BECTON DICKINSON EURO FINANCE S.À R.L FILES FOR OFFERING OF €800 MILLION 4.029% NOTES DUE 2036 - SEC FILING Source text for Eikon: [ID:n0001140361-24-028859] Further company cover
B
Reuters - 3 maanden geleden

Becton, Dickinson And Company Files For Offering Of €1 Billion 3.828% Notes Due 2032 -SEC Filing

BRIEF-Becton, Dickinson And Company Files For Offering Of €1 Billion 3.828% Notes Due 2032 -SEC Filing June 4 (Reuters) - Becton Dickinson and Co BDX.N : BECTON, DICKINSON AND COMPANY FILES FOR OFFERING OF €1 BILLION 3.828% NOTES DUE 2032 -SEC FILING Source text for Eikon: [ID:n0001140361-24-028858] Further company coverage: BDX.N
B

Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.